Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
MomAze versus mometasone, azelastine, and placebo in seasonal allergic rhinitis
2021-004050-31Phase 3Completed
- Sponsor
- Lek
- Start
- Dec 2021
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of mometasone furoate + azelastine, mometasone and azelastine in seasonal allergic rhinitis (SAR) (4 arms), sponsored by Lek. Primary endpoint: Change from baseline in daily Total Nasal Symptom Score during first 7 days. Started Dec 2021; status: completed.
02
Drugs
mometasone furoate + azelastinemometasoneazelastine
03
Conditions
seasonal allergic rhinitis (SAR)
Beyond the preview
Go deeper on 2021-004050-31.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2021-004050-31.